Agenda Cardiovascular Disease in Latin America Prevalence Rates of CV Risk Factors Results From Several Studies in Latin Americans CV Mortality in Latin America CV Risk Factor Reduction Combination Therapy vs Placebo ID: 739770
Download Presentation The PPT/PDF document "Select Topics in Cardiovascular Medicine" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Select Topics in Cardiovascular MedicineSlide2
Agenda Slide3
Cardiovascular Disease in Latin AmericaSlide4
Prevalence Rates of CV Risk Factors: Results From Several Studies in Latin AmericansSlide5
CV Mortality in Latin AmericaSlide6
CV Risk Factor Reduction: Combination Therapy vs PlaceboSlide7
Baseline Factors Associated With 4-Year Outcomes in Latin American Patients of the REACH RegistrySlide8
Summary and ConclusionsSlide9
An Integral Approach to HypertensionSlide10
ESH/ESC/JNC8 BP Treatment RecommendationsSlide11
Results From the SPRINT Trial:
SBP > 130? > 120?Slide12
Controversy Surrounding BP Measurement in SPRINTSlide13
Masked and NTH in the ARTS-DN ABPM Substudy With FinerenoneSlide14
Treating Prehypertension to Reduce Incidence of CV Disease/EventsSlide15
Summary and ConclusionsSlide16
New Insights Into Dyslipidemia Therapy: Controlling Lipids to Reduce CV RiskSlide17
Changes in CV Mortality in Selected Regions, 1990-2013 Slide18
Intervention Strategies Based on CV Risk Factors and Cholesterol LevelsSlide19
Targets and Strategies for Cholesterol Reduction: Moving Beyond StatinsSlide20
PCSK9 Inhibitors for Dyslipidemia:
Results of the FOURIER StudySlide21
Summary and ConclusionsSlide22
Heart Failure: How Can We Improve Timely Diagnosis and Effective Treatment? Slide23
Death Rates for Patients Hospitalized With HF: Europe and Latin AmericaSlide24
Common Comorbidities Associated With HFSlide25
HF: Diagnostic AlgorithmSlide26
Primary Endpoint Results: CANTOSSlide27
Effects of FCM on Hospitalizations and Mortality Rates: A Meta-AnalysisSlide28
Summary and ConclusionsSlide29
Future Strategies for the Prevention of CVD in
Latin AmericaSlide30
Introduction and OverviewSlide31
COMPASS: Rivaroxaban With or Without Aspirin in Stable CVDSlide32
Cumulative Incidence of the Primary Outcome (CV Death, Stroke, or MI)Slide33
COMPASS Subgroup Analysis: PADSlide34
COMPASS Results: Net Clinical BenefitSlide35
CANTOS Trial: Study DesignSlide36
CANTOS Trial: Primary Endpoint ResultsSlide37
CANTOS Trial: Selected AEsSlide38
New Treatments and Cost/Benefit Considerations in Latin AmericaSlide39
Selected Risk Factors: Results From the INTERHEART Latin America StudySlide40
Summary and ConclusionsSlide41
Select Topics in Cardiovascular MedicineSlide42
Summary and Conclusions (1 of 2)Slide43
Summary and Conclusions (2 of 2)Slide44
AbbreviationsSlide45
Abbreviations (cont)Slide46
Abbreviations (cont)Slide47
Abbreviations (cont)